01 Our Science

02 Our Team

03 Pipeline

04 News

05 Publications

06 Contact

01 Our Science

02 Our Team

03 Pipeline

04 News

05 Publications

06 Contact

Transforming the Treatment of Cancer & Inflammatory Diseases

Play Video

See our technology in action

Our Technology

Our unique and proprietary epithelial stem cell cloning platform stemECHO provides unprecedented resolution at the cellular level and has led to the discovery of the underlying mechanism via pathogenic stem cells to cure certain forms of cancer and inflammatory diseases.

Tract has identified drugs that selectively target these pathogenic stem cells in inflammatory airway and intestinal diseases and certain forms of cancer.

Additionally, with our FAP prodrug technology, Tract has the potential to transform how cancer and inflammatory diseases are treated worldwide.

Learn More

Our Mission

We believe we can cure the incurable.

We aspire to enhance the lives of patients suffering from cancer, inflammation and other conditions by changing what’s possible in drug discovery and regenerative medicine.

Our Strategy

Novel therapies

Discover and develop novel therapies to cure or alleviate cancer, metaplasia and inflammatory disease that selectively target the underlying cause.

Novel therapies

Discover and develop novel therapies to cure or alleviate cancer, metaplasia and inflammatory disease that selectively target the underlying cause.

Novel therapies

Discover and develop novel therapies to cure or alleviate cancer, metaplasia and inflammatory disease that selectively target the underlying cause.

Pipeline

Build a robust pipeline of preclinical and clinical assets alone and/or in partnership with established category leaders in cancer and inflammation.

Pipeline

Build a robust pipeline of preclinical and clinical assets alone and/or in partnership with established category leaders in cancer and inflammation.

Pipeline

Build a robust pipeline of preclinical and clinical assets alone and/or in partnership with established category leaders in cancer and inflammation.

Partnership

Build businesses in partnership with the established leaders in diagnostics and regenerative medicine.

Partnership

Build businesses in partnership with the established leaders in diagnostics and regenerative medicine.

Partnership

Build businesses in partnership with the established leaders in diagnostics and regenerative medicine.

stemEcho is a proprietary technology that will allow us to clone epithelial stem cells millions of times while preserving their genetic integrity.

This is achieved by leveraging the fixed identity of transcription factors - key elements that regulate the function and identity of these stem cells. These transcription factors ensure the stem cells remain undifferentiated as they are replicated so that we grow pure colonies of them.

The result? A uniform population of cells, identical in every respect to the original.

One of the most promising applications is in the treatment of cancers and inflammatory diseases. By maintaining the genetic consistency of the cloned cells, researchers can study disease mechanisms with unprecedented precision. This opens the door to new diagnostic tools and therapies that target the root causes of these conditions.

stemECHO, our groundbreaking technology, allows us to clone and characterize the role of epithelial stem cells in the pathogenesis of inflammation and cancer. These insights will fundamentally change the treatment of certain forms of inflammatory diseases and cancers.

This technology could significantly enhance the future of treatment and prevention, making personalized medicine a standard of care. Tract Bio is pioneering the future of healthcare, transforming our knowledge of epithelial stem cell biology into life-changing therapies. The journey to a healthier world begins at the cellular level.

Explore Our Video Library

1/5
The Powerful Technology of Tract Bio's FAP Prodrugs
Tract's fibroblast-activated protein (FAP) prodrugs can enhances drug effectiveness and reduce side effects.
2/5
Tract Bio's stemECHO Technology
stemECHO is making breakthroughs in cancer and chronic, inflammatory diseases.
3/5
The Future of Biotech
stemECHO's innovative role in identifying disease targets and growth opportunities in developing drugs to cure cancer and inflammatory diseases.
4/5
The Transformation of Therapeutics and Diagnostics with stemECHO
stemECHO technology can help create personalized medicine for patients, saving hospitals money and providing faster care.
5/5
Tract Bio Brand Anthem
Tract Bio and its stemECHO technology are at the forefront of disease prevention and cure.

1/5
The Powerful Technology of Tract Bio's FAP Prodrugs
Tract's fibroblast-activated protein (FAP) prodrugs can enhances drug effectiveness and reduce side effects.
2/5
Tract Bio's stemECHO Technology
stemECHO is making breakthroughs in cancer and chronic, inflammatory diseases.
3/5
The Future of Biotech
stemECHO's innovative role in identifying disease targets and growth opportunities in developing drugs to cure cancer and inflammatory diseases.
4/5
The Transformation of Therapeutics and Diagnostics with stemECHO
stemECHO technology can help create personalized medicine for patients, saving hospitals money and providing faster care.
5/5
Tract Bio Brand Anthem
Tract Bio and its stemECHO technology are at the forefront of disease prevention and cure.

1/5
The Powerful Technology of Tract Bio's FAP Prodrugs
Tract's fibroblast-activated protein (FAP) prodrugs can enhances drug effectiveness and reduce side effects.
2/5
Tract Bio's stemECHO Technology
stemECHO is making breakthroughs in cancer and chronic, inflammatory diseases.
3/5
The Future of Biotech
stemECHO's innovative role in identifying disease targets and growth opportunities in developing drugs to cure cancer and inflammatory diseases.
4/5
The Transformation of Therapeutics and Diagnostics with stemECHO
stemECHO technology can help create personalized medicine for patients, saving hospitals money and providing faster care.
5/5
Tract Bio Brand Anthem
Tract Bio and its stemECHO technology are at the forefront of disease prevention and cure.

Our Team

Our Scientific Founders are pioneers in stem cell biology and disease pathogenesis of epithelial tissue.

Their research has been widely published in peer reviewed top tier journals such as Cell and Nature.

Frank McKeon, PhD

Co-Founder, Scientific Team

Wa Xian, PhD

Co-Founder, Scientific Team

Leadership &
Board of Directors

Richard Russell

Chief Executive Officer, Board Member

Chris Galloway, MD

Chief Medical and Development Officer

Joseph Suarez

Chief Financial Officer

Robert Izard, J.D.

General Counsel, Board Chair

John Noseworthy, MD

Board Member

Ian Banwell

Board Member

Charlie Izard

Board Member

Mark J. Adler, MD

Board Member

Kristiina Vuori, MD

Board Member